Haleon PLC
HLN10.185USD
-0.125-1.21%
Handelsschluss 04/25, 16:00（ET）Kurse um 15 Minuten verzögert
92.21BMarktkapitalisierung
63.94KGV TTM
mehr Informationen über Haleon PLC Unternehmen
Haleon plc is a consumer healthcare company. The Company's product portfolio includes five categories, including oral health, vitamins, minerals, and supplements (VMS), pain relief, respiratory health, digestive health and others. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA and LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
Unternehmensinformationen
Unternehmens-codeHLN
Name des UnternehmensHaleon PLC
IPO-datumJul 18, 2022
Gegründet am2021
CEOMr. Brian Mcnamara
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJul 18
AddresseBuilding 5, First Floor
StadtWEYBRIDGE
BörseLondon Stock Exchange
LandUnited Kingdom
PostleitzahlKT13 0NY
Telefon441932822000
Websitehttps://www.haleon.com/
Unternehmens-codeHLN
IPO-datumJul 18, 2022
Gegründet am2021
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
441.03K
+0.36%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ed Petter
Mr. Ed Petter
Chief Corporate Affairs Officer
Chief Corporate Affairs Officer
--
--
Ms. Tracy Clarke
Ms. Tracy Clarke
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Sir Dave Lewis
Sir Dave Lewis
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Keith Choy
Mr. Keith Choy
President, Asia Pacific
President, Asia Pacific
--
--
Mr. Alan J. H. Stewart
Mr. Alan J. H. Stewart
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Brian Mcnamara
Mr. Brian Mcnamara
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
441.03K
+0.36%
Ms. Lisa Paley
Ms. Lisa Paley
President, North America
President, North America
174.31K
+774.13%
Mr. Jo Russell
Mr. Jo Russell
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Adrian Morris
Mr. Adrian Morris
General Counsel
General Counsel
--
--
Ms. Blathnaid Bergin
Ms. Blathnaid Bergin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ed Petter
Mr. Ed Petter
Chief Corporate Affairs Officer
Chief Corporate Affairs Officer
--
--
Umsatzaufteilung
Währung: GBPUpdate-Zeit: Sun, Apr 6
Währung: GBPUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichGBP
Name
Umsatz
Anteil
Oral health
3.31B
29.48%
Pain relief
2.56B
22.83%
Digestive health and other
1.98B
17.66%
Vitamins, minerals and supplements
1.70B
15.10%
Respiratory health
1.68B
14.93%
Nach RegionGBP
Name
Umsatz
Anteil
Rest of the World
6.25B
55.60%
EMEA and LatAm
4.63B
41.23%
Northern America
4.04B
35.98%
US & Puerto Rico
3.62B
32.19%
APAC
2.56B
22.79%
Other
-9.86B
-87.79%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichGBP
Name
Umsatz
Anteil
Oral health
3.31B
29.48%
Pain relief
2.56B
22.83%
Digestive health and other
1.98B
17.66%
Vitamins, minerals and supplements
1.70B
15.10%
Respiratory health
1.68B
14.93%
Aktionäre
Update-Zeit: Thu, Mar 13
Update-Zeit: Thu, Mar 13
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Dodge & Cox
3.96%
Fidelity Management & Research Company LLC
2.10%
ClearBridge Investments, LLC
0.73%
Harding Loevner LP
0.53%
Wellington Management Company, LLP
0.36%
Other
92.31%
Aktionärsstatistik
Aktionäre
Anteil
Dodge & Cox
3.96%
Fidelity Management & Research Company LLC
2.10%
ClearBridge Investments, LLC
0.73%
Harding Loevner LP
0.53%
Wellington Management Company, LLP
0.36%
Other
92.31%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
5.93%
Investment Advisor
4.89%
Hedge Fund
0.66%
Research Firm
0.40%
Bank and Trust
0.14%
Family Office
0.06%
Family Office
0.06%
Family Office
0.06%
Individual Investor
0.02%
Other
87.79%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1036
548.64M
12.15%
-206.45M
2024Q4
1094
745.67M
16.47%
-9.34M
2024Q3
1096
717.29M
15.74%
-81.04M
2024Q2
1078
719.27M
15.75%
-155.43M
2024Q1
1041
707.36M
15.49%
-53.58M
2023Q4
993
691.96M
14.98%
-58.05M
2023Q3
933
688.70M
14.92%
-37.88M
2023Q2
891
677.74M
14.68%
-44.11M
2023Q1
842
667.68M
14.46%
-14.30M
2022Q4
781
634.24M
13.73%
+23.14M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Dodge & Cox
178.74M
3.96%
-427.46K
-0.24%
Dec 31, 2024
Fidelity Management & Research Company LLC
94.69M
2.1%
+3.67M
+4.04%
Dec 31, 2024
ClearBridge Investments, LLC
32.80M
0.73%
-4.57M
-12.22%
Dec 31, 2024
Harding Loevner LP
24.13M
0.53%
-761.67K
-3.06%
Dec 31, 2024
Wellington Management Company, LLP
16.41M
0.36%
+1.08M
+7.04%
Mar 19, 2025
Fidelity Institutional Asset Management
14.14M
0.31%
+236.08K
+1.70%
Dec 31, 2024
Sculptor Capital Management, Inc
8.89M
0.2%
--
--
Dec 31, 2024
Aristotle Capital Management, LLC
8.75M
0.19%
-239.48K
-2.66%
Dec 31, 2024
Douglas C. Lane & Associates
8.62M
0.19%
+161.87K
+1.91%
Dec 31, 2024
Envestnet Asset Management, Inc.
7.63M
0.17%
+58.44K
+0.77%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
VanEck Pharmaceutical ETF
4.76%
ClearBridge Dividend Strategy ESG ETF
2.1%
Fidelity Blue Chip Value ETF
0.92%
SP Funds S&P World (ex-US) ETF
0.37%
ActivePassive International Equity ETF
0.36%
Pacer Trendpilot International ETF
0.23%
Avantis International Equity ETF
0.12%
Avantis Responsible International Equity ETF
0.11%
Avantis International Large Cap Value ETF
0%
Knowledge Leaders Developed World ETF
0%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil4.76%
ClearBridge Dividend Strategy ESG ETF
Anteil2.1%
Fidelity Blue Chip Value ETF
Anteil0.92%
SP Funds S&P World (ex-US) ETF
Anteil0.37%
ActivePassive International Equity ETF
Anteil0.36%
Pacer Trendpilot International ETF
Anteil0.23%
Avantis International Equity ETF
Anteil0.12%
Avantis Responsible International Equity ETF
Anteil0.11%
Avantis International Large Cap Value ETF
Anteil0%
Knowledge Leaders Developed World ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Aug 01, 2024
HLN.NB Final Cash Dividend of gross USD 0.051416 paid on Sep 19, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Sep 19, 2024
Aug 16, 2024
Feb 29, 2024
HLN.NB Interim Cash Dividend of gross USD 0.105268 paid on May 16, 2024 going ex on Mar 14, 2024
Mar 15, 2024
May 16, 2024
Mar 14, 2024
Aug 02, 2023
HLN.NB Final Cash Dividend of gross USD 0.043871 paid on Oct 05, 2023 going ex on Aug 24, 2023
Aug 25, 2023
Oct 05, 2023
Aug 24, 2023
Mar 02, 2023
HLN.NB Interim Cash Dividend of gross USD 0.059732 paid on Apr 27, 2023 going ex on Mar 16, 2023
Mar 17, 2023
Apr 27, 2023
Mar 16, 2023
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten